Retina & Macula · Patient Guide
A dome of fluid
under the retina.
Stress didn't cause it alone.
Central serous chorioretinopathy starts with a leaky choroid, not a damaged retina. Fluid seeps through a weak point in the retinal pigment epithelium and pools beneath the macula, blurring and distorting central vision — usually in a stressed, often steroid-exposed man in his thirties to fifties. Here is what is actually leaking, why steroids of almost any kind are implicated, and what the trial evidence says about when to simply wait.
of onset
estimates vary
resolution window
Section 01 — What's Actually Leaking
Not a retina problem.
A choroid problem
that the retina feels.
Central serous chorioretinopathy (CSCR, also written CSC or CSR) is often described as a retinal condition, but the retina is the victim, not the source. The trouble starts one layer deeper, in the choroid — the dense vascular bed that feeds the outer retina and lies just behind a thin, one-cell-thick barrier called the retinal pigment epithelium (RPE).
In CSCR, the choroid becomes abnormally thick and its vessels abnormally leaky — a pattern now grouped under the broader "pachychoroid disease spectrum." Fluid pressure rises enough to force its way through a weak point in the RPE barrier, and once through, it has nowhere to go but forward, pooling in the potential space between the RPE and the light-sensing neurosensory retina above it. That pocket of subretinal fluid lifts the retina into a shallow, dome-shaped detachment, almost always centred on or near the macula — which is precisely why a fluid problem one layer away from the photoreceptors can still blur central vision within days.
An abnormally thick, hyperpermeable choroid pushes fluid forward under pressure. The retinal pigment epithelium is supposed to act as a one-way pump and barrier holding that fluid back, but at one or more focal points the barrier fails, and fluid leaks through into the space under the neurosensory retina. The resulting fluid dome lifts the retina away from its blood supply and support layer, distorting and dimming vision at the macula. Most first episodes reabsorb on their own as the RPE barrier reseals. Fluid that lingers for months, or keeps recurring, starts to damage the RPE and photoreceptors it was meant to protect.
Section 02 — Interactive
Watch the fluid dome
rise under
a failing RPE barrier.
Move the slider below to see how increasing choroidal congestion pushes more fluid through the retinal pigment epithelium and grows the subretinal fluid dome under the macula. This is a schematic teaching model built to explain the mechanism, not a diagnostic tool or a real OCT scan.
At the low end of the scale, the RPE barrier holds and no fluid accumulates — the normal state for almost everyone, almost all the time. As congestion rises, a focal leak point opens and a small dome of fluid appears; this is the typical picture in a first, acute episode, and it is exactly the stage most cases are caught at when a patient first notices blurred or distorted central vision. At the high end of the scale, representing fluid that has persisted or recurred over months, the dome is larger and the surrounding RPE — not modelled here in anatomical detail — starts to show the diffuse pigment changes that mark chronic disease.
Section 03 — Who Gets It, and Why
The steroid list
is longer than
most patients expect.
CSCR has a distinctive risk profile: it skews strongly toward men, typically in their thirties through fifties, and toward a cluster of factors that all converge on the same hormonal pathway — elevated cortisol or cortisol-like activity. Corticosteroid exposure is the single most consistently replicated risk factor in case-control studies, and it is not limited to steroid eye drops.
| Risk factor | Why it's implicated |
|---|---|
| Corticosteroids, any route | Oral, inhaled, intranasal, topical skin, intra-articular and epidural steroids have all been linked to new or worsened CSCR; not limited to ophthalmic steroid drops |
| Psychological stress / "type A" personality | Elevated endogenous cortisol and catecholamines; a repeatedly observed association across case-control studies, though the exact mechanism is still being worked out |
| Male sex | Consistently over-represented in case series; the biological reason for the sex skew itself is not fully settled |
| Pregnancy | Hormonal and cortisol shifts; typically resolves after delivery |
| Sleep disturbance / obstructive sleep apnea | Reported association in several studies, plausibly via cortisol dysregulation from disrupted sleep |
| Untreated hypertension | Reported as an associated factor in some case-control series, mechanism less clear than the steroid pathway |
| Sympathomimetic use | Decongestants and related stimulant-type drugs reported in some case series; evidence weaker than for corticosteroids |
The corticosteroid link is worth dwelling on because it is the one risk factor a patient and physician can actually act on. Someone using an inhaled steroid for asthma, a nasal spray for seasonal allergies, or a short course of oral steroids for an unrelated flare-up may have no reason to connect that medication to a new blur in one eye. A CSCR work-up routinely includes a specific question about corticosteroid use in any form, precisely because patients do not always think to volunteer it unprompted.
Section 04 — Symptoms & Diagnosis
A blur that makes
things look
smaller than they are.
The symptom pattern is fairly distinctive once recognised. Central vision blurs or dims, straight lines can appear bent (metamorphopsia), and a genuinely unusual clue — micropsia, where objects appear smaller than they actually are — shows up often enough in CSCR to be a useful pointer toward the diagnosis. Some patients also notice a subtle shift toward hyperopia, since the elevated retina sits slightly out of its normal focal plane.
Because the symptoms — sudden blur, distortion, a grey or dim patch of central vision — overlap with other causes of acute central vision change, CSCR is a diagnosis made on retinal imaging rather than symptoms alone. It sits on a differential that includes wet age-related macular degeneration, macular oedema from retinal vein occlusion, and other causes of subretinal or intraretinal fluid, which is precisely why OCT and angiography, not description of symptoms, make the call.
Section 05 — The Evidence
Most cases resolve.
The trial evidence
is about the ones that don't.
CSCR was first characterised by Gass in 1967 as a distinct clinical entity, and the natural history described then still holds up reasonably well: a first acute episode very often clears on its own within a few months as the RPE reseals and reabsorbs the fluid. That self-limited course is why observation, not immediate treatment, is the standard first step for an uncomplicated first episode.
Illustrative visualisation of direction and rough magnitude reported in the cited natural-history and trial literature (Gass, PLACE, VICI) — see References. Not pooled meta-analytic effect sizes; exact resolution and response rates vary by series.
For chronic or recurrent disease that doesn't clear on its own, the strongest randomised evidence is the PLACE trial, which compared half-dose photodynamic therapy against high-density subthreshold micropulse laser and found photodynamic therapy the more effective option for achieving complete fluid resolution in chronic CSCR. Photodynamic therapy uses a photosensitising drug activated by low-intensity laser light targeted at the hyperpermeable choroidal area identified on ICG angiography, at a reduced ("half") dose or fluence specifically chosen to limit collateral damage to the choroid and RPE.
Eplerenone, a mineralocorticoid receptor antagonist, looked promising in smaller earlier studies based on the theory that mineralocorticoid receptor activation in choroidal blood vessels drives the hyperpermeability. The VICI trial, a large randomised, double-blind, placebo-controlled study, tested this directly in chronic CSCR patients with fluid present for more than four months and did not find a statistically significant visual acuity benefit over placebo — a useful, if disappointing, example of a mechanistically plausible treatment not holding up under rigorous testing. Anti-VEGF injections, the mainstay for neovascular AMD and diabetic macular oedema, are generally not considered effective for classic CSCR itself, since the leak is a barrier-function problem rather than abnormal new vessel growth — though anti-VEGF does have a role if a separate complication, secondary choroidal neovascularisation, develops in longstanding disease.
reclassify as chronic
characterised CSCR
involved
Section 06 — Risk, Honestly Stated
Watching and waiting
is not the same
as doing nothing.
Because most first episodes resolve on their own, the biggest practical risk in CSCR management is not any single treatment's side-effect profile — it is treating too early (exposing a patient to laser or drug risk for fluid that would have cleared anyway) or treating too late (letting genuinely chronic fluid sit untreated until the RPE and photoreceptors are permanently damaged). Both directions carry real, documented downsides.
| Approach | Main risk | When it's the right call |
|---|---|---|
| Observation | Delayed treatment if the case turns out to be chronic rather than acute | First episode, fluid present less than ~3–4 months, no prior episodes |
| Focal laser photocoagulation | Permanent scotoma if the leak point is too close to the fovea; not usable for many leak locations | A well-defined leak point safely away from the centre of the macula |
| Half-dose photodynamic therapy | Transient visual disturbance, rare choroidal ischaemia at higher doses — part of why "half-dose" was adopted | Chronic or recurrent disease, especially with diffuse choroidal hyperpermeability on ICGA |
| Eplerenone / spironolactone | Hyperkalaemia risk, requires electrolyte monitoring, and the VICI trial found no clear visual benefit over placebo | Limited role given the negative trial data; some clinicians still trial it selectively |
| Continuing an implicated corticosteroid untouched | Ongoing driver of fluid recurrence and progression to chronic disease | Never the intended approach — always worth a documented conversation with the prescribing physician about alternatives |
Section 07 — Where This Intersects Cataract Surgery
Active fluid can quietly
throw off
a biometry reading.
CSCR is a retina condition, not a cataract-surgical one, and Agaaz does not manufacture anything used to treat it — there is no product tie-in to force here. But a history of CSCR is genuinely relevant if the same patient later needs cataract surgery, which is common enough in the same middle-aged-to-older population that it is worth a short, honest note.
A patient in their late fifties with early cataract and a history of resolved CSCR from a decade earlier presents with new blur. If that blur is in fact a CSCR recurrence rather than cataract progression, biometry and refraction taken during the active fluid episode can be unreliable — an elevated macula can shift manifest refraction toward hyperopia and distort the axial-length and keratometry inputs an IOL power calculation depends on. Confirming the macula has flattened and stabilised on OCT before finalising IOL power avoids a preventable refractive surprise after surgery.
The second, quieter consideration is chronic CSCR with longstanding RPE atrophy: even after successful cataract surgery, visual potential is capped by whatever permanent macular damage the CSCR left behind, which is a conversation worth having before surgery rather than after, in the same way pre-existing macular disease from other causes such as age-related macular degeneration is discussed ahead of cataract counselling.
Section 08 — FAQ
Frequently asked questions
about CSCR.
Central serous chorioretinopathy (CSCR, sometimes CSC or CSR) is a condition where fluid leaks from the choroid, the vascular layer behind the retina, through a weak point in the retinal pigment epithelium (RPE) barrier and collects underneath the neurosensory retina at or near the macula. That pocket of fluid lifts the retina slightly off its supporting layer, which blurs or dims central vision and can make straight lines look bent or objects look smaller than they are.
There is a real, repeatedly observed association between CSCR and elevated cortisol, whether from psychological stress, a "type A" stress-prone personality pattern, or corticosteroid medication, though the exact biological chain from stress hormones to a leaky choroid is still being worked out. It is best understood as one strong risk factor among several rather than a single proven cause, and plenty of cases occur without any clear stress trigger identified.
Yes. The association is with corticosteroids from essentially any route, including oral tablets, inhaled steroids for asthma, nasal sprays for allergies, topical skin creams, and injected steroids for joint pain or epidural use, not only ophthalmic steroid drops. Many patients are surprised to learn a medication they never associated with their eyes at all is on the list of recognised triggers, which is why a CSCR work-up usually includes a careful medication history.
A first, acute episode very often does resolve without treatment as the fluid is gradually reabsorbed, commonly over a period of roughly a few weeks to a few months, and vision typically returns close to baseline. That is why observation is the standard first step for a straightforward acute case. The exception is fluid that persists well beyond that window or keeps recurring, which is reclassified as chronic CSCR and carries a real risk of lasting retinal pigment epithelium damage if left untreated indefinitely.
Acute CSCR is a single, self-limited episode of subretinal fluid that typically clears within a few months with observation alone. Chronic CSCR is fluid that persists beyond roughly four to six months, or repeated recurrent episodes, and is associated with widespread, often diffuse retinal pigment epithelium changes visible on imaging as gravitational tracks. The distinction matters because chronic disease carries a materially higher risk of permanent photoreceptor and RPE damage, and is managed more actively rather than simply watched.
The first step is identifying and, where medically appropriate and possible, reducing any corticosteroid exposure driving it. For fluid that persists, half-dose or half-fluence photodynamic therapy targeted at the leaking choroidal area has the strongest trial evidence, including a randomised comparison against subthreshold micropulse laser. Focal laser photocoagulation can treat a leak point well away from the centre of the macula. Eplerenone, a mineralocorticoid receptor antagonist, was tested in a large randomised trial and did not show a meaningful benefit over placebo for chronic disease, despite earlier smaller studies suggesting promise. Anti-VEGF injections are not considered effective for classic CSCR itself, since the underlying problem is not the kind of abnormal blood vessel growth anti-VEGF drugs target, though they are used if a separate complication, choroidal neovascularisation, develops.
It can. Active subretinal fluid distorts the macula and can shift the eye's refraction, most classically toward hyperopia, which makes biometry and IOL power calculation performed during an active episode unreliable. Surgeons generally prefer to confirm the fluid has resolved and the macular contour has stabilised on OCT before finalising IOL power measurements, and a history of chronic CSCR with RPE atrophy is also relevant to counselling a patient on the visual outcome ceiling cataract surgery alone can realistically deliver.
References & Evidence Base
Peer-reviewed
citations.
Continue Reading
Related guides
from Beyond Vision.
Retina & Macula · Patient Guide
A dome of fluid
under the retina.
Stress didn't cause it alone.
Central serous chorioretinopathy starts with a leaky choroid, not a damaged retina. Fluid seeps through a weak point in the retinal pigment epithelium and pools beneath the macula, blurring and distorting central vision — usually in a stressed, often steroid-exposed man in his thirties to fifties. Here is what is actually leaking, why steroids of almost any kind are implicated, and what the trial evidence says about when to simply wait.
of onset
estimates vary
resolution window
Section 01 — What's Actually Leaking
Not a retina problem.
A choroid problem
that the retina feels.
Central serous chorioretinopathy (CSCR, also written CSC or CSR) is often described as a retinal condition, but the retina is the victim, not the source. The trouble starts one layer deeper, in the choroid — the dense vascular bed that feeds the outer retina and lies just behind a thin, one-cell-thick barrier called the retinal pigment epithelium (RPE).
In CSCR, the choroid becomes abnormally thick and its vessels abnormally leaky — a pattern now grouped under the broader "pachychoroid disease spectrum." Fluid pressure rises enough to force its way through a weak point in the RPE barrier, and once through, it has nowhere to go but forward, pooling in the potential space between the RPE and the light-sensing neurosensory retina above it. That pocket of subretinal fluid lifts the retina into a shallow, dome-shaped detachment, almost always centred on or near the macula — which is precisely why a fluid problem one layer away from the photoreceptors can still blur central vision within days.
An abnormally thick, hyperpermeable choroid pushes fluid forward under pressure. The retinal pigment epithelium is supposed to act as a one-way pump and barrier holding that fluid back, but at one or more focal points the barrier fails, and fluid leaks through into the space under the neurosensory retina. The resulting fluid dome lifts the retina away from its blood supply and support layer, distorting and dimming vision at the macula. Most first episodes reabsorb on their own as the RPE barrier reseals. Fluid that lingers for months, or keeps recurring, starts to damage the RPE and photoreceptors it was meant to protect.
Section 02 — Interactive
Watch the fluid dome
rise under
a failing RPE barrier.
Move the slider below to see how increasing choroidal congestion pushes more fluid through the retinal pigment epithelium and grows the subretinal fluid dome under the macula. This is a schematic teaching model built to explain the mechanism, not a diagnostic tool or a real OCT scan.
At the low end of the scale, the RPE barrier holds and no fluid accumulates — the normal state for almost everyone, almost all the time. As congestion rises, a focal leak point opens and a small dome of fluid appears; this is the typical picture in a first, acute episode, and it is exactly the stage most cases are caught at when a patient first notices blurred or distorted central vision. At the high end of the scale, representing fluid that has persisted or recurred over months, the dome is larger and the surrounding RPE — not modelled here in anatomical detail — starts to show the diffuse pigment changes that mark chronic disease.
Section 03 — Who Gets It, and Why
The steroid list
is longer than
most patients expect.
CSCR has a distinctive risk profile: it skews strongly toward men, typically in their thirties through fifties, and toward a cluster of factors that all converge on the same hormonal pathway — elevated cortisol or cortisol-like activity. Corticosteroid exposure is the single most consistently replicated risk factor in case-control studies, and it is not limited to steroid eye drops.
| Risk factor | Why it's implicated |
|---|---|
| Corticosteroids, any route | Oral, inhaled, intranasal, topical skin, intra-articular and epidural steroids have all been linked to new or worsened CSCR; not limited to ophthalmic steroid drops |
| Psychological stress / "type A" personality | Elevated endogenous cortisol and catecholamines; a repeatedly observed association across case-control studies, though the exact mechanism is still being worked out |
| Male sex | Consistently over-represented in case series; the biological reason for the sex skew itself is not fully settled |
| Pregnancy | Hormonal and cortisol shifts; typically resolves after delivery |
| Sleep disturbance / obstructive sleep apnea | Reported association in several studies, plausibly via cortisol dysregulation from disrupted sleep |
| Untreated hypertension | Reported as an associated factor in some case-control series, mechanism less clear than the steroid pathway |
| Sympathomimetic use | Decongestants and related stimulant-type drugs reported in some case series; evidence weaker than for corticosteroids |
The corticosteroid link is worth dwelling on because it is the one risk factor a patient and physician can actually act on. Someone using an inhaled steroid for asthma, a nasal spray for seasonal allergies, or a short course of oral steroids for an unrelated flare-up may have no reason to connect that medication to a new blur in one eye. A CSCR work-up routinely includes a specific question about corticosteroid use in any form, precisely because patients do not always think to volunteer it unprompted.
Section 04 — Symptoms & Diagnosis
A blur that makes
things look
smaller than they are.
The symptom pattern is fairly distinctive once recognised. Central vision blurs or dims, straight lines can appear bent (metamorphopsia), and a genuinely unusual clue — micropsia, where objects appear smaller than they actually are — shows up often enough in CSCR to be a useful pointer toward the diagnosis. Some patients also notice a subtle shift toward hyperopia, since the elevated retina sits slightly out of its normal focal plane.
Because the symptoms — sudden blur, distortion, a grey or dim patch of central vision — overlap with other causes of acute central vision change, CSCR is a diagnosis made on retinal imaging rather than symptoms alone. It sits on a differential that includes wet age-related macular degeneration, macular oedema from retinal vein occlusion, and other causes of subretinal or intraretinal fluid, which is precisely why OCT and angiography, not description of symptoms, make the call.
Section 05 — The Evidence
Most cases resolve.
The trial evidence
is about the ones that don't.
CSCR was first characterised by Gass in 1967 as a distinct clinical entity, and the natural history described then still holds up reasonably well: a first acute episode very often clears on its own within a few months as the RPE reseals and reabsorbs the fluid. That self-limited course is why observation, not immediate treatment, is the standard first step for an uncomplicated first episode.
Illustrative visualisation of direction and rough magnitude reported in the cited natural-history and trial literature (Gass, PLACE, VICI) — see References. Not pooled meta-analytic effect sizes; exact resolution and response rates vary by series.
For chronic or recurrent disease that doesn't clear on its own, the strongest randomised evidence is the PLACE trial, which compared half-dose photodynamic therapy against high-density subthreshold micropulse laser and found photodynamic therapy the more effective option for achieving complete fluid resolution in chronic CSCR. Photodynamic therapy uses a photosensitising drug activated by low-intensity laser light targeted at the hyperpermeable choroidal area identified on ICG angiography, at a reduced ("half") dose or fluence specifically chosen to limit collateral damage to the choroid and RPE.
Eplerenone, a mineralocorticoid receptor antagonist, looked promising in smaller earlier studies based on the theory that mineralocorticoid receptor activation in choroidal blood vessels drives the hyperpermeability. The VICI trial, a large randomised, double-blind, placebo-controlled study, tested this directly in chronic CSCR patients with fluid present for more than four months and did not find a statistically significant visual acuity benefit over placebo — a useful, if disappointing, example of a mechanistically plausible treatment not holding up under rigorous testing. Anti-VEGF injections, the mainstay for neovascular AMD and diabetic macular oedema, are generally not considered effective for classic CSCR itself, since the leak is a barrier-function problem rather than abnormal new vessel growth — though anti-VEGF does have a role if a separate complication, secondary choroidal neovascularisation, develops in longstanding disease.
reclassify as chronic
characterised CSCR
involved
Section 06 — Risk, Honestly Stated
Watching and waiting
is not the same
as doing nothing.
Because most first episodes resolve on their own, the biggest practical risk in CSCR management is not any single treatment's side-effect profile — it is treating too early (exposing a patient to laser or drug risk for fluid that would have cleared anyway) or treating too late (letting genuinely chronic fluid sit untreated until the RPE and photoreceptors are permanently damaged). Both directions carry real, documented downsides.
| Approach | Main risk | When it's the right call |
|---|---|---|
| Observation | Delayed treatment if the case turns out to be chronic rather than acute | First episode, fluid present less than ~3–4 months, no prior episodes |
| Focal laser photocoagulation | Permanent scotoma if the leak point is too close to the fovea; not usable for many leak locations | A well-defined leak point safely away from the centre of the macula |
| Half-dose photodynamic therapy | Transient visual disturbance, rare choroidal ischaemia at higher doses — part of why "half-dose" was adopted | Chronic or recurrent disease, especially with diffuse choroidal hyperpermeability on ICGA |
| Eplerenone / spironolactone | Hyperkalaemia risk, requires electrolyte monitoring, and the VICI trial found no clear visual benefit over placebo | Limited role given the negative trial data; some clinicians still trial it selectively |
| Continuing an implicated corticosteroid untouched | Ongoing driver of fluid recurrence and progression to chronic disease | Never the intended approach — always worth a documented conversation with the prescribing physician about alternatives |
Section 07 — Where This Intersects Cataract Surgery
Active fluid can quietly
throw off
a biometry reading.
CSCR is a retina condition, not a cataract-surgical one, and Agaaz does not manufacture anything used to treat it — there is no product tie-in to force here. But a history of CSCR is genuinely relevant if the same patient later needs cataract surgery, which is common enough in the same middle-aged-to-older population that it is worth a short, honest note.
A patient in their late fifties with early cataract and a history of resolved CSCR from a decade earlier presents with new blur. If that blur is in fact a CSCR recurrence rather than cataract progression, biometry and refraction taken during the active fluid episode can be unreliable — an elevated macula can shift manifest refraction toward hyperopia and distort the axial-length and keratometry inputs an IOL power calculation depends on. Confirming the macula has flattened and stabilised on OCT before finalising IOL power avoids a preventable refractive surprise after surgery.
The second, quieter consideration is chronic CSCR with longstanding RPE atrophy: even after successful cataract surgery, visual potential is capped by whatever permanent macular damage the CSCR left behind, which is a conversation worth having before surgery rather than after, in the same way pre-existing macular disease from other causes such as age-related macular degeneration is discussed ahead of cataract counselling.
Section 08 — FAQ
Frequently asked questions
about CSCR.
Central serous chorioretinopathy (CSCR, sometimes CSC or CSR) is a condition where fluid leaks from the choroid, the vascular layer behind the retina, through a weak point in the retinal pigment epithelium (RPE) barrier and collects underneath the neurosensory retina at or near the macula. That pocket of fluid lifts the retina slightly off its supporting layer, which blurs or dims central vision and can make straight lines look bent or objects look smaller than they are.
There is a real, repeatedly observed association between CSCR and elevated cortisol, whether from psychological stress, a "type A" stress-prone personality pattern, or corticosteroid medication, though the exact biological chain from stress hormones to a leaky choroid is still being worked out. It is best understood as one strong risk factor among several rather than a single proven cause, and plenty of cases occur without any clear stress trigger identified.
Yes. The association is with corticosteroids from essentially any route, including oral tablets, inhaled steroids for asthma, nasal sprays for allergies, topical skin creams, and injected steroids for joint pain or epidural use, not only ophthalmic steroid drops. Many patients are surprised to learn a medication they never associated with their eyes at all is on the list of recognised triggers, which is why a CSCR work-up usually includes a careful medication history.
A first, acute episode very often does resolve without treatment as the fluid is gradually reabsorbed, commonly over a period of roughly a few weeks to a few months, and vision typically returns close to baseline. That is why observation is the standard first step for a straightforward acute case. The exception is fluid that persists well beyond that window or keeps recurring, which is reclassified as chronic CSCR and carries a real risk of lasting retinal pigment epithelium damage if left untreated indefinitely.
Acute CSCR is a single, self-limited episode of subretinal fluid that typically clears within a few months with observation alone. Chronic CSCR is fluid that persists beyond roughly four to six months, or repeated recurrent episodes, and is associated with widespread, often diffuse retinal pigment epithelium changes visible on imaging as gravitational tracks. The distinction matters because chronic disease carries a materially higher risk of permanent photoreceptor and RPE damage, and is managed more actively rather than simply watched.
The first step is identifying and, where medically appropriate and possible, reducing any corticosteroid exposure driving it. For fluid that persists, half-dose or half-fluence photodynamic therapy targeted at the leaking choroidal area has the strongest trial evidence, including a randomised comparison against subthreshold micropulse laser. Focal laser photocoagulation can treat a leak point well away from the centre of the macula. Eplerenone, a mineralocorticoid receptor antagonist, was tested in a large randomised trial and did not show a meaningful benefit over placebo for chronic disease, despite earlier smaller studies suggesting promise. Anti-VEGF injections are not considered effective for classic CSCR itself, since the underlying problem is not the kind of abnormal blood vessel growth anti-VEGF drugs target, though they are used if a separate complication, choroidal neovascularisation, develops.
It can. Active subretinal fluid distorts the macula and can shift the eye's refraction, most classically toward hyperopia, which makes biometry and IOL power calculation performed during an active episode unreliable. Surgeons generally prefer to confirm the fluid has resolved and the macular contour has stabilised on OCT before finalising IOL power measurements, and a history of chronic CSCR with RPE atrophy is also relevant to counselling a patient on the visual outcome ceiling cataract surgery alone can realistically deliver.
References & Evidence Base
Peer-reviewed
citations.
Continue Reading
Related guides
from Beyond Vision.
Start writing here...
Central Serous Chorioretinopathy: Why Stress and Steroids Put Fluid Under Your Retina (2026 Guide)